<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>462</serviceExecutionTime><Drug id="100134"><DrugName>benznidazole (Chagas disease), Humanigen</DrugName><DrugNamesKey><Name id="42818845">benznidazole</Name></DrugNamesKey><DrugSynonyms><Name><Value>benznidazole</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>HWP-002</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>benznidazole (Chagas disease), Savant Neglected diseases</Value></Name><Name><Value>benznidazole (Chagas disease), KaloBios</Value></Name><Name><Value>benznidazole (Chagas disease), Humanigen</Value></Name><Name><Value>22994-85-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1071868">Savant HWP Inc</CompanyOriginator><CompaniesSecondary><Company id="1071868">Savant HWP Inc</Company><Company id="1117016">Savant Neglected Diseases LLC</Company><Company id="31508">Humanigen Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1071868" type="Company"><TargetEntity id="5037650358" type="organizationId">Savant HWP Inc</TargetEntity></SourceEntity><SourceEntity id="31508" type="Company"><TargetEntity id="4297292034" type="organizationId">Humanigen Inc</TargetEntity></SourceEntity><SourceEntity id="335" type="ciIndication"><TargetEntity id="B57" type="ICD10"></TargetEntity><TargetEntity id="D014355" type="MeSH"></TargetEntity><TargetEntity id="-1708981827" type="omicsDisease"></TargetEntity><TargetEntity id="1599" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2638" type="Action"><TargetEntity id="4959" type="Mechanism">Drugs Targeting Parasite Proteins</TargetEntity><TargetEntity id="4622" type="Mechanism">Drugs Targeting Plasmodium falciparum Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="CU">Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="335">Trypanosoma cruzi infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="2638">Antiparasitic</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>P</Code><Name>PARASITOLOGY</Name></Ephmra></EphmraCodes><LastModificationDate>2018-12-07T12:16:23.000Z</LastModificationDate><ChangeDateLast>2017-08-09T00:00:00.000Z</ChangeDateLast><AddedDate>2015-12-08T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="31508" linkType="Company"&gt;Humanigen&lt;/ulink&gt; (previously KaloBios Pharmaceuticals), through asset acquisition from &lt;ulink linkID="1117016" linkType="Company"&gt;Savant Neglected Diseases&lt;/ulink&gt;, was developing an oral  formulation of &lt;ulink linkID="52081" linkType="Drug"&gt;benznidazole&lt;/ulink&gt; (presumed to be HWP-002), for the potential  treatment of Trypanosoma cruzi infection (Chagas disease) [&lt;ulink linkID="1718206" linkType="Reference"&gt;1718206&lt;/ulink&gt;], [&lt;ulink linkID="1718632" linkType="Reference"&gt;1718632&lt;/ulink&gt;], [&lt;ulink linkID="1916446" linkType="Reference"&gt;1916446&lt;/ulink&gt;], [&lt;ulink linkID="1951205" linkType="Reference"&gt;1951205&lt;/ulink&gt;]. In August 2017, enrollment and follow-up of subjects in a  bioavailability study was completed [&lt;ulink linkID="1951764" linkType="Reference"&gt;1951764&lt;/ulink&gt;]. However, by September 2018, the drug was no longer listed on Humanigen's pipeline [&lt;ulink linkID="2076545" linkType="Reference"&gt;2076545&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2015, a NDA filing was expected in 2016 [&lt;ulink linkID="1718206" linkType="Reference"&gt;1718206&lt;/ulink&gt;], [&lt;ulink linkID="1718632" linkType="Reference"&gt;1718632&lt;/ulink&gt;]. In December 2015, the company planned to register the drug  with the US FDA. The company  also planned to  file for FDA Priority Review Voucher (PRV)  [&lt;ulink linkID="1721382" linkType="Reference"&gt;1721382&lt;/ulink&gt;]. In December 2016, the company   completed a face-to-face meeting with the US FDA to review its proposed development plans for benznidazole. FDA's Division of Anti-Infective Products addressed the company's questions and provided guidance on preparation of an acceptable package for benznidazole [&lt;ulink linkID="1884520" linkType="Reference"&gt;1884520&lt;/ulink&gt;]. In January 2017, Humanigen reported positive guidance  from the   meeting with FDA. The  proposed 505(b)(2) approach was acceptable to FDA and if approved as a treatment for Chagas disease, benznidazole was   expected to be eligible for a PRV  [&lt;ulink linkID="1890507" linkType="Reference"&gt;1890507&lt;/ulink&gt;]. In April 2017, an NDA   was planned to    be submitted to the US FDA in the first quarter of 2018 [&lt;ulink linkID="1916446" linkType="Reference"&gt;1916446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, Humanigen planned to file for Orphan Drug and Fast Track designation [&lt;ulink linkID="1718206" linkType="Reference"&gt;1718206&lt;/ulink&gt;], [&lt;ulink linkID="1718632" linkType="Reference"&gt;1718632&lt;/ulink&gt;]. In July 2017, the US FDA granted Orphan designation to benznidazole for the treatment of Chagas disease [&lt;ulink linkID="1944380" linkType="Reference"&gt;1944380&lt;/ulink&gt;], [&lt;ulink linkID="1948214" linkType="Reference"&gt;1948214&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2017, Humanigen had completed enrollment and follow-up of subjects in a  bioavailability study. At that time, preliminary interpretation of the data and  final study report were expected in October and in the fourth quarter of 2017 respectively [&lt;ulink linkID="1951764" linkType="Reference"&gt;1951764&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, an IND application was planned to    be submitted to the US FDA in May 2017 [&lt;ulink linkID="1916446" linkType="Reference"&gt;1916446&lt;/ulink&gt;]. In May 2017, an IND was filed to the US FDA   [&lt;ulink linkID="1932783" linkType="Reference"&gt;1932783&lt;/ulink&gt;]. Later that month, the FDA accepted the IND; in June 2017, the IND became effective [&lt;ulink linkID="1941407" linkType="Reference"&gt;1941407&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2015, Humanigen planned to initiate pharmacokinetic, CMC and toxicology studies in  2015/2016   [&lt;ulink linkID="1718206" linkType="Reference"&gt;1718206&lt;/ulink&gt;], [&lt;ulink linkID="1718632" linkType="Reference"&gt;1718632&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2013, development of HWP-002 by Savant was ongoing [&lt;ulink linkID="1464433" linkType="Reference"&gt;1464433&lt;/ulink&gt;]. In January 2015, development was ongoing [&lt;ulink linkID="1686109" linkType="Reference"&gt;1686109&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="31508">Humanigen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1117016">Savant Neglected Diseases LLC</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-03T00:00:00.000Z</StatusDate><Source id="1718206" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1117016">Savant Neglected Diseases LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-03T00:00:00.000Z</StatusDate><Source id="1718206" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1071868">Savant HWP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-08-13T00:00:00.000Z</StatusDate><Source id="1464433" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31508">Humanigen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-03T00:00:00.000Z</StatusDate><Source id="1718206" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="31508">Humanigen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-08T00:00:00.000Z</StatusDate><Source id="1951764" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="31508">Humanigen Inc</OwnerCompany><Country id="US">US</Country><Indication id="335">Trypanosoma cruzi infection</Indication><AwardedIndication>Treatment of Chagas Disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-03T00:00:00.000Z</MileStoneDate><Source id="1718206" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="31508">Humanigen Inc</OwnerCompany><Country id="US">US</Country><Indication id="335">Trypanosoma cruzi infection</Indication><AwardedIndication>Treatment of Chagas disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-05T00:00:00.000Z</MileStoneDate><Source id="1944380" type="PR"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1071868">Savant HWP Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="31508">Humanigen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccc(cc1)CNC(=O)Cn2ccnc2[N+](=O)[O-]</Smiles></StructureSmiles><Deals><Deal id="157478" title="KaloBios acquires worldwide rights of Savant's benznidazole for Chagas disease                            "></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="100632"><DrugName>TP-271 (oral, bacterial infections), Tetraphase Pharmaceuticals</DrugName><DrugSynonyms><Name><Value>TP-271</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TP-271 (oral, bacterial infections), Tetraphase Pharmaceuticals</Value></Name></DrugSynonyms><CompanyOriginator id="1038619">Tetraphase Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="1038619">Tetraphase Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1038619" type="Company"><TargetEntity id="4297657884" type="organizationId">Tetraphase Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="40">Bacterial infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="1539">Tetracycline</Action><Action id="463">Ribosome binding agent</Action><Action id="1594">Antibacterial</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-14T10:47:53.000Z</LastModificationDate><ChangeDateLast>2019-02-18T00:00:00.000Z</ChangeDateLast><AddedDate>2016-01-21T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1038619" linkType="Company"&gt;Tetraphase Pharmaceuticals&lt;/ulink&gt; was   developing TP-271 (structure shown), a broad spectrum fluorocycline  antibiotic   from a series of  tetracycline analogs, for the potential oral treatment of multidrug-resistant bacterial infections and bacterial respiratory tract infections including  community-acquired respiratory infections and biothreat pathogens such as Francisella tularensis,  Yersinia pestis, and Bacillus anthracis [&lt;ulink linkID="1127523" linkType="Reference"&gt;1127523&lt;/ulink&gt;], [&lt;ulink linkID="1127527" linkType="Reference"&gt;1127527&lt;/ulink&gt;], [&lt;ulink linkID="1231938" linkType="Reference"&gt;1231938&lt;/ulink&gt;], [&lt;ulink linkID="1190235" linkType="Reference"&gt;1190235&lt;/ulink&gt;],  [&lt;ulink linkID="1127406" linkType="Reference"&gt;1127406&lt;/ulink&gt;], [&lt;ulink linkID="1907059" linkType="Reference"&gt;1907059&lt;/ulink&gt;].    However, in June 2019, Tetraphase announced  a corporate reorganization and closed  its  internal research group to focus on the launch of its approved &lt;ulink linkID="64411" linkType="Drug"&gt;eravacycline&lt;/ulink&gt; antibacterial; at that time, the company was seeking to outlicense  its early-stage   candidates [&lt;ulink linkID="2162070" linkType="Reference"&gt;2162070&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, a phase I single-ascending-dose trial  was initiated   [&lt;ulink linkID="1893994" linkType="Reference"&gt;1893994&lt;/ulink&gt;]. In March 2018, a phase I multiple-ascending-dose trial  was initiated [&lt;ulink linkID="2115118" linkType="Reference"&gt;2115118&lt;/ulink&gt;]. In April 2019, clinical data were presented [&lt;ulink linkID="2140379" linkType="Reference"&gt;2140379&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Tetraphase is also developing an &lt;ulink linkID="75969" linkType="Drug"&gt;iv formulation of TP-271&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By January 2019, the oral form of the drug had been  granted US Qualified Infectious Disease Product and Fast Track designations [&lt;ulink linkID="2114781" linkType="Reference"&gt;2114781&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In March 2018, a randomized, placebo-controlled, double-blind, phase I trial (&lt;ulink linkID="331055" linkType="Protocol"&gt;NCT03450187&lt;/ulink&gt;; TP-271-004) was initiated in the US to assess multiple ascending doses of oral TP‑271 in healthy subjects (expected n = 40). The primary endpoints were safety, tolerability, and pharmacokinetics. In April 2018, the trial was expected to complete in January 2019 [&lt;ulink linkID="2115118" linkType="Reference"&gt;2115118&lt;/ulink&gt;]. In April 2019, clinical data were presented at the 29th ECCMID in Amsterdam, the Netherlands. Multiple doses of po TP-271 led to high plasma exposures. TP-271 was generally well-tolerated with nausea and vomiting being the most common AEs mostly at higher doses and did not lead to study drug discontinuation. Among 30 TP-271-trreated subjects, 24 reported AEs [&lt;ulink linkID="2140379" linkType="Reference"&gt;2140379&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, a randomized, double-blind, placebo-controlled, phase I trial (&lt;ulink linkID="285486" linkType="Protocol"&gt;NCT03024034&lt;/ulink&gt;; TP-271-003; 15-0061) was initiated in the US to assess single ascending doses of oral TP‑271 in healthy subjects (expected n = 56). The primary endpoints were safety, tolerability, and pharmacokinetics. In February 2018, the trial was expected to complete in May 2018 [&lt;ulink linkID="1893994" linkType="Reference"&gt;1893994&lt;/ulink&gt;]. In April 2019, clinical data were presented at the 29th ECCMID in Amsterdam, the Netherlands.TP-271 was generally well-tolerated with nausea and vomiting being the most common adverse events (AEs) mostly at higher doses and did not lead to study drug discontinuation. Among 36 TP-271-trreated subjects, 16 reported AEs  [&lt;ulink linkID="2140379" linkType="Reference"&gt;2140379&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By August 2015, an IND had been filed for TP-271 [&lt;ulink linkID="1684162" linkType="Reference"&gt;1684162&lt;/ulink&gt;]; by September 2015, the IND  had been accepted by the FDA [&lt;ulink linkID="1691577" linkType="Reference"&gt;1691577&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2016, preclinical data were presented at the 2016 ASM Microbe Conference in Boston, MA. In cynomolgus monkeys, positive blood culture or quantifiable qPCR result was observed at any time point during the study and F tularenis was detected only in mediastinal lymph node for 19% of TP-271-treated animals but vehicle control animals were bacteremic before death and quantifiable levels of F tularenis in all tissues including lung, liver, spleen, mediastinal lymph node was observed [&lt;ulink linkID="1771617" linkType="Reference"&gt;1771617&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. In BALB/c mice, treatment with TP-271 (3 (post-exposure prophylaxis (PEP) only), 6, 12 or 18 mg/kg, ip, qd for 21 days) initiated at 24 (PEP) or 48 (treatment model) h showed protection against anthrax and all animals exposed to TP-271 survived and no relapse occurred, while two doxycycline (40 mg/kg, ip, bid) exposed animals died [&lt;ulink linkID="1693352" linkType="Reference"&gt;1693352&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 25th ECCMID in Copenhagen, Denmark. TP-271 had MIC value of 0.0625 and 0.001 microg/ml, against Staphylococcus aureus and Streptococcus pneumonia, respectively. Protein binding of TP-271 was higher in plasma with increase in TP-271 concentration than in epithelial lining fluid [&lt;ulink linkID="1653426" linkType="Reference"&gt;1653426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, preclinical data were presented at the 54th ICAAC Meeting in Washington, DC. In gonorrhoeae infected female BALB/c mice, TP-271 (6, 12 and 28 mg/kg) after 4 to 5 days of administration significantly reduced the infection. All doses of TP-271 significantly reduced CFU/ml after 4 to 5 days, but a single dose of &lt;ulink linkID="44384" linkType="Drug"&gt;ceftriaxone&lt;/ulink&gt; (15 mg/kg) completely cleared the infection at 24 h after treatment [&lt;ulink linkID="1590102" linkType="Reference"&gt;1590102&lt;/ulink&gt;]. From the same conference data were presented. In a post-exposure prophylaxis for pneumonic plague infected BALB/c mice model, TP-271(6, 12 and 28 mg/kg, ten single   daily ip doses) dose dependently decreased the infection. On day 11 (end of dosing) and 24 (end of post-dose/relapse period), all surviving animals had no detectable Y pestis in blood, lung, spleen and liver [&lt;ulink linkID="1590103" linkType="Reference"&gt;1590103&lt;/ulink&gt;]. Further data were  presented at the same conference.   TP-271 showed activity against methicillin-resistant MRSA clinical isolates with MIC values in the range of 0.0625 to 0.125 microg/ml [&lt;ulink linkID="1590104" linkType="Reference"&gt;1590104&lt;/ulink&gt;].  Further data were  presented at the same conference. TP-271 showed significant activity against both susceptible and resistant clinical isolates with MIC values in the range of 1 to 2 ng/ml [&lt;ulink linkID="1590106" linkType="Reference"&gt;1590106&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2014, preclinical data presented at the 114th ASM General Meeting in Boston, MA, showed TP-271 to have in vitro activity against a panel of Neisseria gonorrhoeae isolates, including drug resistance profiles [&lt;ulink linkID="1583460" linkType="Reference"&gt;1583460&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, preclinical data were presented at the 53rd ICAAC Meeting in Denver, CO. In Francisella tularensis-infected female 6 to 8 week old BALB/c mice treated with TP-271 (3, 6, 12 or 18 mg/kg, qd, ip), the respective Cmax and AUC (last) values were in the range of 0.917 to 3.12 microg/ml and 7.39 to 31.20 microg.h/ml on day 1 after single dose. In murine post-exposure prophylaxis tularemia model, TP-271 showed protection and also improved survival [&lt;ulink linkID="1472600" linkType="Reference"&gt;1472600&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data on the activity of TP-271 against community-acquired bacterial pneumonia were presented at the 23rd European Congress of Clinical Microbiology and Infectious Disease in Berlin, Germany [&lt;ulink linkID="1420217" linkType="Reference"&gt;1420217&lt;/ulink&gt;]. In April 2013, preclinical data were presented at the 23rd ECCMID  in Berlin, Germany. The respective MIC50 values of TP-271 against various Streptococcus pneumoniae, and Staphylococcus aureus strains were &amp;lt;/= 0.016 and 0.06 to 0.12 microg/ml, and also against Legionella pneumophila, Chlamydophila pneumoniae and Mycoplasma pneumoniae were 0.25, 4 and 0.001 microg/ml [&lt;ulink linkID="1406537" linkType="Reference"&gt;1406537&lt;/ulink&gt;], [&lt;ulink linkID="1412049" linkType="Reference"&gt;1412049&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  September 2012, preclinical data were presented at the 52nd ICAAC Meeting in San Francisco, CA. TP-271 had MIC90 values in the range of &amp;lt;/= 0.0008 to 0.5 microg/ml against Y pestis, B anthracis, Francisella tularensis and Burkholderia mallei. It also displayed potent activities against multidrug resistant respiratory pathogens, including Streptococcus pneumoniae, MRSA, S pyogenes, Hemophilus influenzae and Moraxella catarrhalis [&lt;ulink linkID="1321131" linkType="Reference"&gt;1321131&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, TP-271 was to be evaluated in preclinical safety and efficacy studies for tularemia and respiratory infections with  testing for activity against anthrax and plague was also planned [&lt;ulink linkID="1230471" linkType="Reference"&gt;1230471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011,  data were presented at the 51st ICAAC meeting in Chicago, IL. The activity of TP-271 was evaluated against 22 respiratory Mycobacterium abscessus clinical isolates. The MIC50 and MIC90 values of TP-271 were 0.25 and 0.5 microg/ml, respectively and the respective values of &lt;ulink linkID="12978" linkType="Drug"&gt;moxifloxacin&lt;/ulink&gt; were 4 and 8 microg/ml. Tetracycline and doxycycline with MIC value range of 8 to &amp;gt; 64 microg/ml and 2 to &amp;gt; 64 microg/ml, respectively, were found to be much less active than TP-271, when tested against subsets of M abscessus [&lt;ulink linkID="1219595" linkType="Reference"&gt;1219595&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, the company planned to assess the efficacy of TP-271 against Francisella tularensis in mice. Also, the company planned to evaluate oral bioavailability in chimpanzees, efficacy in a mouse model of pneumonic plague, efficacy in a mouse model of tularemia, pharmacokinetic/pharmacodynamics of TP-271 in a murine model of MRSA infection and to collect IND-enabling data to support safety in multiple species and in in vitro screens [&lt;ulink linkID="1297485" linkType="Reference"&gt;1297485&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, further preclinical data were presented at the 50th ICAAC meeting in Boston MA. It was proposed that the bacterial ribosome was the site of action. The activity of the compound was not affected by ribosome protection mechanisms, and was  unaffected or minimally affected by common tetracycline efflux pumps [&lt;ulink linkID="1127564" linkType="Reference"&gt;1127564&lt;/ulink&gt;]. The compound was found to have in vitro activity against tetracycline-resistant strains of Staphylococcus aureus, Enterococcus faecalis and S pneumoniae [&lt;ulink linkID="1127406" linkType="Reference"&gt;1127406&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, preclinical data were presented at the 50th ICAAC meeting in Boston, MA. In animal respiratory infection models,  TP-271 showed activity against MRSA, S epidermidis and Haemophilus influenzae when administered orally. Additional in vitro studies demonstrated activity against a number of multidrug-resistant respiratory pathogens and biothreat pathogens [&lt;ulink linkID="1127523" linkType="Reference"&gt;1127523&lt;/ulink&gt;], [&lt;ulink linkID="1131133" linkType="Reference"&gt;1131133&lt;/ulink&gt;]. The compound also was found to have significantly higher activity against Legionella pneumophila compared with tetracycline in vitro  [&lt;ulink linkID="1127527" linkType="Reference"&gt;1127527&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1038619">Tetraphase Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-06-12T00:00:00.000Z</StatusDate><Source id="2162070" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1038619">Tetraphase Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-15T00:00:00.000Z</StatusDate><Source id="1127406" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1038619">Tetraphase Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-02T00:00:00.000Z</StatusDate><Source id="1893994" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1038619">Tetraphase Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="40">Bacterial infection</Indication><AwardedIndication>Treatment of bacterial infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-29T00:00:00.000Z</MileStoneDate><Source id="2114781" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="1038619">Tetraphase Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="40">Bacterial infection</Indication><AwardedIndication>Treatment of bacterial infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-29T00:00:00.000Z</MileStoneDate><Source id="2114781" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2157332" linkType="reference" linkID="2157332"&gt;2157332&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1038619">Tetraphase Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1053803">CUBRC</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CN1CCC[C@H]1C(=O)Nc2cc(c3c(c2O)C(=O)C4=C([C@]5([C@@H](C[C@@H]4C3)[C@@H](C(=C(C5=O)C(=O)N)O)N(C)C)O)O)F</Smiles></StructureSmiles><Deals><Deal id="136636" title="CUBRC to support the development of TP-271 for Tetraphase Pharmaceuticals to treat tularemia and bacterial pneumonia"></Deal><Deal id="142427" title="NIAID to award CUBRC funding for the development of TP-271 to treat multidrug-resistant bacterial infections          "></Deal><Deal id="146144" title="NIAID to award Tetraphase Pharmaceuticals funding for the development of TP-271 "></Deal></Deals><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>